Clovis Oncology (NASDAQ:CLVS) was upgraded by stock analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a report released on Thursday, Marketbeat reports. The brokerage presently has a $72.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s target price points to a potential upside of 26.67% from the stock’s previous close. The analysts noted that the move was a valuation call.
Other analysts have also issued research reports about the company. BidaskClub lowered Clovis Oncology from a “sell” rating to a “strong sell” rating in a research note on Friday, February 9th. Morgan Stanley dropped their price objective on Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $125.00 price objective on shares of Clovis Oncology in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. Clovis Oncology currently has an average rating of “Buy” and an average price target of $90.37.
Shares of Clovis Oncology (NASDAQ:CLVS) opened at $56.84 on Thursday. The stock has a market capitalization of $2,640.00, a P/E ratio of -6.86 and a beta of 1.05. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45.
In related news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now owns 25,618 shares in the company, valued at $1,537,080. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $59.16, for a total value of $177,480.00. Following the transaction, the insider now owns 183,571 shares of the company’s stock, valued at approximately $10,860,060.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,500 shares of company stock valued at $1,364,595. Insiders own 12.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its holdings in shares of Clovis Oncology by 21.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,725 shares of the biopharmaceutical company’s stock valued at $349,000 after acquiring an additional 655 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Clovis Oncology by 16.1% during the third quarter. Amalgamated Bank now owns 5,587 shares of the biopharmaceutical company’s stock valued at $460,000 after acquiring an additional 776 shares in the last quarter. Greenwood Capital Associates LLC raised its holdings in shares of Clovis Oncology by 21.6% during the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 996 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Clovis Oncology by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 436,518 shares of the biopharmaceutical company’s stock valued at $29,683,000 after acquiring an additional 1,206 shares in the last quarter. Finally, Capital Analysts LLC bought a new position in shares of Clovis Oncology during the third quarter valued at approximately $111,000.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://transcriptdaily.com/2018/02/24/clovis-oncology-clvs-raised-to-outperform-at-evercore-isi.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.